Introduction of new pharmacological agents is expected in addition to nutritional and exercise interventions.
8 years after the first publication, EWGSOP has published the new consensus of sarcopenia diagnosis to update the original definition, in which they tried to reflect scientific and clinical evidence that has been built so far [9] . In the updated consensus paper on sarcopenia, EWGSOP focuses on low muscle strength as a key characteristic of sarcopenia, uses low muscle quantity and quality to confirm the sarcopenia diagnosis, and defines severe sarcopenia when poor physical performance is present. They also provide cut-off points for measurements of variables for the diagnosis of sarcopenia. The revised diagnostic criteria are quite well appreciated, considering the age-related changes of skeletal muscle and availability of measurements in various settings. In the aging process, skeletal muscle starts to decline, followed by the decline of power, strength and gait speed. Additionally, grip strength has been shown to better predict adverse health outcomes than skeletal muscle mass [10] . Therefore, it would be reasonable to use grip strength as the primary measure to make sarcopenia diagnosis. However, there are several issues that need to be discussed in more details. The first one is the screening by SARC-F. Although this is a good screening tool for sarcopenia, its low sensitivity may not be appropriate for the screening purpose [11] . The second is which outcome measures are the most appropriate for sarcopenia interventions. Although this topic might be out of scope of this article, it would be better to address this for the future sarcopenia intervention studies. The third is about the diagnosis of secondary sarcopenia in clinical settings. Although we have several outcome studies in the community settings, few studies have been done to address how we should make a diagnosis of sarcopenia in clinical settings, such as patients with chronic renal failure, heart failure, rheumatoid arthritis and so on. More evidence is needed to address this issue.
In spite of these issues, EWGSOP2 will encourage more research in the field of sarcopenia for the prevention of adverse health outcomes that will produce a heavy burden for our societies.
